 |
Gang Xie, PhD
Research Assistant Professor |
Dr. Xie received his BS in Biochemistry from Nanjing University, China and his PhD in Chemistry from South Dakota State University. During his postdoctoral study at Montana State University, he investigated the molecular mechanism of iron acquisition by human pathogens for vaccine development. As part of our group (2010-2015), Dr. Xie worked on the metabolism and pharmacokinetics of novel anti-cancer agents under study in our lab. He also investigated their mechanism of action.
He is now collaborating with us on drug development.
Selected Publications
- Xie G, Cheng KW, Huang L, Rigas B. The in vitro metabolism of phospho-sulindac amide, a novel potential anticancer agent. Biochem Pharmacol. 2014;91(2):249-55.
- Wong CC, Cheng KW, Papayannis I, Mattheolabakis G, Huang L, Xie G, Ouyang N, Rigas B. Phospho-NSAIDs have enhanced efficacy in mice lacking plasma carboxylesterase: implications for their clinical pharmacology. Pharm Res. 201;32(5):1663-75. doi: 10.1007/s11095-014-1565-2.
- Mackenzie GG, Bartels LE, Xie G, Papayannis I, Alston N, Vrankova K, Ouyang N, Rigas B. A novel Ras inhibitor (MDC-1016) reduces human pancreatic tumor growth in mice. Neoplasia. 2013;15(10):1184-95.
- Xie G, Zhou D, Cheng KW, Wong CC, Rigas B. Comparative in vitro metabolism of phospho-tyrosol-indomethacin by mice, rats and humans. Biochem Pharmacol. 2013 Apr 15;85(8):1195-202.
- Xie G, Wong CC, Cheng KW, Huang L, Constantinides PP, Rigas B. Regioselective oxidation of phospho-NSAIDs by human cytochrome P450 and flavin monooxygenase isoforms: implications for their pharmacokinetic properties and safety. Br J Pharmacol. 201;167(1):222-32.
For a complete list of publications, Click Here and Here.
